Published in Infect Immun on June 01, 2004
Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev (2014) 2.20
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact (2011) 1.45
Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol (2006) 1.12
Oral immunization with recombinant lactobacillus plantarum induces a protective immune response in mice with Lyme disease. Clin Vaccine Immunol (2008) 1.05
Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol (2006) 1.05
Inactivation of the CovR/S virulence regulator impairs infection in an improved murine model of Streptococcus pyogenes naso-pharyngeal infection. PLoS One (2013) 1.02
A new plasmid vector for DNA delivery using lactococci. Genet Vaccines Ther (2009) 0.99
A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity. Infect Immun (2009) 0.88
Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice. BMC Microbiol (2009) 0.83
Expression of a biologically active GFP-α(S1)-casein fusion protein in Lactococcus lactis. Curr Microbiol (2012) 0.82
Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs (2011) 0.80
Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. BMC Microbiol (2006) 0.78
The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model. BMC Gastroenterol (2013) 0.77
A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet Med Int (2013) 0.77
The AgI/II family adhesin AspA is required for respiratory infection by Streptococcus pyogenes. PLoS One (2013) 0.76
Recombinant Lactococcus lactis Expressing Haemagglutinin from a Polish Avian H5N1 Isolate and Its Immunological Effect in Preliminary Animal Trials. Biomed Res Int (2017) 0.75
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci. Clin Vaccine Immunol (2014) 0.75
Immunogenicity of a divalent group A streptococcal vaccine. Rheumatol Int (2012) 0.75
Current knowledge of type-specific M antigens of group A streptococci. J Immunol (1962) 14.71
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A (1988) 3.82
Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein. J Exp Med (1985) 3.23
emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis (1999) 3.12
Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis (1996) 2.51
The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med (1988) 2.42
Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol (1982) 2.27
Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun (1988) 2.24
Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol (1993) 2.05
Immunochemical localization and amino acid sequences of crossreactive epitopes within the group A streptococcal M6 protein. J Exp Med (1986) 2.03
Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol (1997) 2.02
Immunological responses to fed protein antigens in mice. II. Oral tolerance for CMI is due to activation of cyclophosphamide-sensitive cells by gut-processed antigen. Immunology (1983) 1.99
Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci U S A (1995) 1.80
Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol (1997) 1.77
Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol (1998) 1.76
Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun (1996) 1.71
Spontaneous M6 protein size mutants of group A streptococci display variation in antigenic and opsonogenic epitopes. Proc Natl Acad Sci U S A (1988) 1.62
Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine (2001) 1.56
Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science (1989) 1.54
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol (1987) 1.53
Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek (1996) 1.51
Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol (1990) 1.50
M cells in Peyer's patches of the intestine. Int Rev Cytol (1996) 1.47
Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun (1995) 1.44
Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med (1988) 1.39
Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol (2002) 1.33
Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol (2001) 1.25
Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun (2001) 1.22
Difference between bacterial and food antigens in mucosal immunogenicity. Infect Immun (1989) 1.22
Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol (1992) 1.20
Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood (2003) 1.20
Lactic acid bacteria as live vaccines. Curr Issues Mol Biol (2000) 1.20
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 1.19
The role of antigen recognition and suppressor cells in mice with oral tolerance to ovalbumin. Immunology (1985) 1.14
Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis. FEMS Immunol Med Microbiol (1996) 1.09
History of oral tolerance and mucosal immunity. Ann N Y Acad Sci (1996) 1.06
Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine (2001) 1.04
Salivary antibodies and systemic tolerance in mice after oral immunization with bacterial antigens. Ann N Y Acad Sci (1983) 1.03
Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine (2002) 1.02
Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice. FEMS Microbiol Lett (2002) 1.01
Diversity of antibody-mediated immunity at the mucosal barrier. Infect Immun (1999) 1.01
Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect Immun (1990) 0.99
Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells. Infect Immun (1998) 0.97
Engineering the gram-positive cell surface for construction of bacterial vaccine vectors. Methods (1999) 0.95
Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol (1995) 0.95
Oral administration of TNP-Lactobacillus conjugates in mice: a model for evaluation of mucosal and systemic immune responses and memory formation elicited by transformed lactobacilli. Res Microbiol (1991) 0.93
Live bacterial delivery systems for development of mucosal vaccines. Curr Opin Mol Ther (2000) 0.91
Surface expression of the conserved C repeat region of streptococcal M6 protein within the Pip bacteriophage receptor of Lactococcus lactis. Appl Environ Microbiol (2001) 0.82
Antibodies to cytomegalo and Epstein-Barr viruses in human saliva and gingival fluid. New Microbiol (1998) 0.79
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. J Antimicrob Chemother (2006) 1.36
Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother (2008) 1.31
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Differential activation of the NF-kappaB-like factors Relish and Dif in Drosophila melanogaster by fungi and Gram-positive bacteria. J Biol Chem (2004) 1.19
Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother (2005) 1.15
Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture. Antimicrob Agents Chemother (2006) 1.15
Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. J Antimicrob Chemother (2010) 1.09
Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun (2006) 1.07
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother (2009) 1.07
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother (2010) 0.91
Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother (2013) 0.91
Bacterial resistance to antisense peptide phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother (2012) 0.89
Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer. Antimicrob Agents Chemother (2009) 0.89
Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun (2005) 0.88
Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis. Nucleic Acid Ther (2012) 0.86
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine (2010) 0.84
Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by gram-positive commensal vectors. Infect Immun (2002) 0.84
Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys. PLoS One (2011) 0.83
Subcellular location of phage infection protein (Pip) in Lactococcus lactis. Can J Microbiol (2006) 0.83
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother (2012) 0.81
Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother (2012) 0.79
Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmid. Can J Microbiol (2007) 0.78
A Novel Lactococcal Vaccine Expressing a Peptide from the M2 Antigen of H5N2 Highly Pathogenic Avian Influenza A Virus Prolongs Survival of Vaccinated Chickens. Vet Med Int (2013) 0.77
Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine (2002) 0.77
Development of PLEX, a plasmid-based expression system for production of heterologous gene products by the gram-positive bacteria Streptococcus gordonii. Protein Expr Purif (2005) 0.77
Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection. PLoS One (2013) 0.75